ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1472

Body Mass Index Does Not Affect Response to Rituximab in Patients with Rheumatoid Arthritis: Results from Turkbio Registry

Suleyman Serdar Koca1, Ahmet Karatas2, Burak Oz3, Ediz Dalkilic4, Gerçek Can5, Yavuz Pehlivan6, Ayten Yazici7, Nevsun Inanc8, Ayse Cefle9, Zeypen Erturk10, Servet Akar11, Soner Senel12, Merih Birlik13, Nurullah Akkoc14 and Fatos Onen15, 1Department of Rheumatology, Firat University School of Medicine, Elazig, Turkey, 2Department of Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, 3Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, 4Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, 5Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, 6Department of Rheumatology, Uludag University, Bursa, Turkey, 7Rheumatology, Kocaeli University, Kocaeli, Turkey, 8Departement of İnternal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, 9Rheumatology, Kocaeli University, School of Medicine, Rheumatology, Kocaeli, Turkey, 10Department of Rheumatology, Marmara Univeristy School of Medicine, Istanbul, Turkey, 11Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, 12Rheumatology, Kayseri Erciyes University, School of Medicine, Rheumatology, Kayseri, Turkey, 13Department of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, 14Rheumatology, Private Practice, Rheumatology, İzmir, Turkey, 15Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: ,

Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Adipose tissue produces several inflammatory mediators. Thus, obesity affects the disease course and the responses to the anti-rheumatic agents in inflammatory diseases. Several previous reports have documented that obesity decrease the response rate to anti-TNF-α agents in rheumatoid arthritis (RA). The aim of the study was to determine whether body mass index (BMI) is involved in the response to rituximab in RA.

Methods: Data on patient characteristics, diagnosis, previous treatment and outcomes have been collected since 2011 in Turkish Biologic (TURKBIO) Registry. By the end of May 2017, 206 RA patients, received rituximab from the TURKBIO registry, were included in the analysis. Demographic and clinical data including age, sex, disease type, disease duration, and previous or current treatment with DMARDs and biological drug durations are stored in the database. Kaplan-Meier survival analysis was performed to estimate the drug survival. Subgroups were compared by log-rank.

Results: 32.5% patients were normal/underweight, 67.5% were overweight and 28.6% were obese. Mean age, female percentage, DAS28-CRP and VAS were higher in obese patients than non-obese ones (Table 1). Rituximab treatment was ongoing 71.2% in obese and 63.3% in non-obese patients (p=0.279). Median drug survival duration was 77 months in obese patients and 62 months in non-obese ones (p=0.053). Estimated drug survival rates for rituximab were not statistically significantly different in the obese and non-obese patients (Fig. 1).

Conclusion: It is known that adipose tissue increases TNF-α level and enhances cellular immunity. Since its act on humoral immunity may be limited, obesity does not affect the response to rituximab.

References: 1. Iannone F, Fanizzi R, Notarnicola A, Scioscia C, Anelli MG, Lapadula G. Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients. Joint Bone Spine. 2015;82:187-91. 2. Gardette A, Ottaviani S, Sellam J, Berenbaum F, Lioté F, Fautrel B, Palazzo E, Meyer A, Sibilia J, Dieudé P. Body mass index and response to abatacept in rheumatoid arthritis. Eur J Clin Invest. 2016;46:1048-52. 3. Ottaviani S, Gardette A, Roy C, Tubach F, Gill G, Palazzo E, Meyer O, Dieudé P. Body Mass Index and response to rituximab in rheumatoid arthritis. Joint Bone Spine. 2015;82:432-6.

Disclosure: S. S. Koca, None; A. Karatas, None; B. Oz, None; E. Dalkilic, AbbVie, 2,AbbVie, MSD, Roche, UCB and Pfizer, 9; G. Can, None; Y. Pehlivan, None; A. Yazici, None; N. Inanc, None; A. Cefle, None; Z. Erturk, None; S. Akar, None; S. Senel, None; M. Birlik, None; N. Akkoc, None; F. Onen, None.

To cite this abstract in AMA style:

Koca SS, Karatas A, Oz B, Dalkilic E, Can G, Pehlivan Y, Yazici A, Inanc N, Cefle A, Erturk Z, Akar S, Senel S, Birlik M, Akkoc N, Onen F. Body Mass Index Does Not Affect Response to Rituximab in Patients with Rheumatoid Arthritis: Results from Turkbio Registry [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/body-mass-index-does-not-affect-response-to-rituximab-in-patients-with-rheumatoid-arthritis-results-from-turkbio-registry/. Accessed .

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/body-mass-index-does-not-affect-response-to-rituximab-in-patients-with-rheumatoid-arthritis-results-from-turkbio-registry/